Track Divi's Laboratories live share price with 52 week high and low, chart views, fundamentals, financial statements, ratios, peer comparison, dividends, bonuses/splits and company details for beginner-friendly stock research.
Switch between 1 Day, 5 Day, 1 Month and 1 Year chart views. Chart data is useful for trend awareness, not as a standalone investment signal.
These metrics refresh from the latest available market data where possible. Market data can be delayed or temporarily unavailable, so verify important numbers from NSE, BSE or company filings before taking action.
Divi's Laboratories Limited is an Indian pharmaceutical manufacturing company based in Hyderabad. The company is known for active pharmaceutical ingredients, intermediates, custom synthesis and nutraceutical ingredients supplied to customers across global healthcare and nutrition markets.
For customers, Divi's is mainly a manufacturing and development partner that supports scale, process chemistry, quality systems and dependable supply. For investors, it is usually analysed as an API and CDMO-oriented pharma company rather than a branded retail medicine company.
Important monitorables include generic API pricing, custom synthesis growth, product concentration, customer concentration, operating margin, regulatory inspections, capex execution, foreign exchange impact, working capital, free cash flow and return ratios.
Divi's Laboratories is commonly compared with Indian pharmaceutical and API peers. However, peer comparison should adjust for business mix because some peers are formulation-heavy while Divi's has a stronger API, custom synthesis and nutraceutical manufacturing profile.
Divi's Laboratories earns revenue by manufacturing high-volume generic APIs, intermediates and nutraceutical ingredients, and by carrying out custom synthesis work for global pharmaceutical companies. The business depends on chemistry capabilities, large-scale manufacturing, quality systems, customer trust and cost-efficient execution.
In custom synthesis, the company may work with pharmaceutical innovators across the product lifecycle, including process development, scale-up and commercial manufacturing. In generic APIs, sales are influenced by global demand, competitive intensity, pricing, regulatory approvals and production efficiency.
Beginners should remember that a pharma manufacturing business can look strong in one period and softer in another because product mix, currency movement, raw material costs, customer orders and regulatory timelines can affect quarterly results.
The table below explains the company in simple language for customers and retail investors. Segment-level revenue mix should be verified from the latest annual report or investor presentation.
| Segment | What it means | What to monitor |
|---|---|---|
| Generic APIs | Large-volume APIs and intermediates | Volume, pricing, regulatory approvals, global demand and product mix |
| Custom Synthesis / CDMO | Process development and manufacturing for innovator pharma customers | Customer pipeline, molecule lifecycle, capacity availability and confidentiality requirements |
| Nutraceuticals | Carotenoids, vitamins and ingredient formats for nutrition, food, feed and pharma customers | Demand in nutrition markets, formulation support and global customer relationships |
| Manufacturing and R&D Support | Scale-up, process chemistry, quality systems and backward integration | Capex execution, quality record, cost efficiency and raw material security |
Profit and loss data helps investors understand sales, margins, expenses and net profit. Verify the latest audited or reviewed numbers from official company results and exchange filings.
| Particulars | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Sales | ₹7,845 Cr | ₹9,360 Cr | ₹10,560 Cr |
| Expenses | ₹5,635 Cr | ₹6,387 Cr | ₹7,119 Cr |
| Operating Profit | ₹2,210 Cr | ₹2,973 Cr | ₹3,441 Cr |
| OPM | 28% | 32% | 33% |
| Other Income | ₹335 Cr | ₹348 Cr | ₹433 Cr |
| Interest | ₹4 Cr | ₹3 Cr | ₹23 Cr |
| Depreciation | ₹378 Cr | ₹402 Cr | ₹463 Cr |
| Profit Before Tax | ₹2,163 Cr | ₹2,916 Cr | ₹3,388 Cr |
| Net Profit | ₹1,600 Cr | ₹2,191 Cr | ₹2,568 Cr |
| EPS | ₹60.27 | ₹82.53 | ₹96.73 |
| Dividend Payout | 50% | 36% | 31% |
The balance sheet shows how the business is funded and where capital is invested. In a manufacturing company, fixed assets, capital work in progress, cash, working capital and borrowings are important to review.
| Particulars | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Equity Capital | ₹53 Cr | ₹53 Cr | ₹53 Cr |
| Reserves | ₹13,518 Cr | ₹14,916 Cr | ₹16,708 Cr |
| Borrowings | ₹3 Cr | ₹4 Cr | ₹7 Cr |
| Other Liabilities | ₹1,886 Cr | ₹1,948 Cr | ₹3,265 Cr |
| Total Liabilities | ₹15,460 Cr | ₹16,921 Cr | ₹20,033 Cr |
| Fixed Assets | ₹4,739 Cr | ₹5,442 Cr | ₹6,528 Cr |
| Capital Work in Progress | ₹778 Cr | ₹1,022 Cr | ₹2,113 Cr |
| Investments | ₹82 Cr | ₹65 Cr | ₹69 Cr |
| Other Assets | ₹9,861 Cr | ₹10,392 Cr | ₹11,323 Cr |
| Total Assets | ₹15,460 Cr | ₹16,921 Cr | ₹20,033 Cr |
Cash flow helps beginners see whether accounting profits are turning into real cash. For Divi's Laboratories, operating cash flow, capex, free cash flow and working capital movement are useful investor checks.
| Particulars | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Cash from Operating Activity | ₹1,261 Cr | ₹1,653 Cr | ₹2,738 Cr |
| Cash from Investing Activity | -₹269 Cr | -₹804 Cr | -₹2,219 Cr |
| Cash from Financing Activity | -₹799 Cr | -₹799 Cr | -₹804 Cr |
| Net Cash Flow | ₹193 Cr | ₹50 Cr | -₹285 Cr |
| Free Cash Flow | ₹258 Cr | ₹215 Cr | ₹221 Cr |
| CFO / Operating Profit | 74% | 83% | 105% |
Ratios simplify financial analysis, but they should not be used alone. Compare ratios with the company's own history and with peers that have a similar API/CDMO business mix.
| Metric | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| ROCE | 16% | 20% | 22% |
| Return on Equity | 3Y: 15% | 5Y: 17% | 10Y: 18% |
| Compounded Sales Growth | 10Y: 11% | 5Y: 9% | TTM: 13% |
| Compounded Profit Growth | 10Y: 9% | 5Y: 6% | TTM: 20% |
| Stock Price CAGR | 10Y: 20% | 5Y: 10% | 1Y: 3% |
| Debtor Days | 100 | 106 | 103 |
| Inventory Days | 364 | 311 | 353 |
| Cash Conversion Cycle | 370 | 330 | 348 |
| Dividend Payout | 50% | 36% | 31% |
This peer table uses the latest available Yahoo Finance quote feed for market data where available. Peer comparison is educational only because companies differ by product mix, geography, regulatory exposure and margin profile.
| Company | Symbol | Business Focus | Market Cap | Price | P/E | Dividend Yield |
|---|---|---|---|---|---|---|
| Divi's Laboratories Ltd | DIVISLAB.NS | APIs, custom synthesis and nutraceutical ingredients | — | — | — | — |
| Sun Pharmaceutical Industries Ltd | SUNPHARMA.NS | Specialty, branded and generic pharmaceuticals | — | — | — | — |
| Cipla Ltd | CIPLA.NS | Respiratory, chronic therapies and global generics | — | — | — | — |
| Dr. Reddy's Laboratories Ltd | DRREDDY.NS | Generics, APIs, biosimilars and pharmaceutical services | — | — | — | — |
| Aurobindo Pharma Ltd | AUROPHARMA.NS | Generics, formulations and APIs | — | — | — | — |
| Laurus Labs Ltd | LAURUSLABS.NS | APIs, formulations, CDMO and biotechnology | — | — | — | — |
Peer valuation, market cap and yield change daily. Verify the latest figures from NSE/BSE, company filings and your broker platform before making any investment decision.
| Year | Dividend Detail | Note |
|---|---|---|
| FY 2025-26 | ₹30 per share noted in recent shareholder communication | Verify AGM approval, record date, ex-date and tax details from NSE/BSE filings |
| FY 2024-25 | Dividend payout shown at 36% | Use annual report and exchange filings for final per-share dividend and payment details |
| FY 2023-24 | Dividend payout shown at 50% | Use company annual report and exchange filings for verified historical dividend data |
| Action | Detail | Note |
|---|---|---|
| Bonus Issue | 1:1 bonus with ex-date in September 2015 | Verify the corporate action history from exchange/company filings before making adjusted-return calculations |
| Bonus Issue | 1:1 bonus with ex-date in July 2009 | Historical corporate action; verify from official records for portfolio or tax work |
| Stock Split | Face value split from ₹10 to ₹2 with ex-date in August 2007 | Face value and split history should be checked from BSE/NSE filings |
| Current Face Value | ₹2.00 | Confirm current face value from latest exchange quote or company filing |
Dividend, bonus and split information can affect eligibility, tax and adjusted returns. Always verify record date, ex-date, entitlement, tax deduction and payment details from official company, NSE and BSE filings.
These FAQs answer common AI-search-style questions about Divi's Laboratories, its products, business model, risks, dividends, corporate actions and investor monitorables.
Divi's Laboratories manufactures active pharmaceutical ingredients, intermediates and nutraceutical ingredients. It also provides custom synthesis and contract development/manufacturing support for global pharmaceutical customers.
The NSE symbol is DIVISLAB and the BSE code is 532488. For live chart and quote data, this page uses the Yahoo Finance compatible symbol DIVISLAB.NS.
The company earns revenue by manufacturing generic APIs, intermediates, nutraceutical ingredients and custom synthesis products for pharmaceutical and nutrition customers. Sales depend on product volumes, pricing, regulatory approvals, customer orders, currency movement and raw material costs.
The main operating areas are generic APIs, custom synthesis for global pharmaceutical companies, intermediates and nutraceutical ingredients such as carotenoids and vitamins.
Divi's Laboratories is commonly tracked as an Indian pharmaceutical manufacturing company with strong focus on APIs, intermediates, custom synthesis and nutraceutical ingredients rather than branded formulations.
Retail investors usually monitor revenue growth, operating margin, capacity utilization, custom synthesis traction, generic API pricing, raw material costs, foreign exchange impact, capex progress, cash generation, return ratios and regulatory updates.
Key risks include pricing pressure in generic APIs, customer concentration in custom synthesis, regulatory observations, currency volatility, raw material cost swings, product concentration, delayed capacity ramp-up and changes in global pharmaceutical supply chains.
Divi's Laboratories has paid dividends in the past. Dividend amount, record date and payment eligibility can change each year, so investors should verify the latest dividend details from company announcements, NSE and BSE filings.
The company has a history of bonus issues and a face value split. Corporate action details should be verified from official exchange filings before making any tax, portfolio or historical return calculation.
Beginners can use the chart to see short-term price movement across 1 day, 5 day, 1 month and 1 year periods. A chart shows price trend only; it should be read together with fundamentals, financials, valuation, risks and official filings.
Divi's Laboratories is more API and custom synthesis focused, while many large pharma peers also have branded generics, domestic formulations, specialty products or broader global formulation businesses. Peer comparison should consider business mix, margins, valuation, growth, regulatory risk and cash generation.
Investors should verify the latest annual reports, quarterly results, shareholding pattern, dividend notices, bonus or split announcements and corporate actions from the company's investor relations page, NSE filings and BSE filings.
No. This page is for educational information, price tracking and basic financial understanding. It does not provide buy, sell or hold recommendations. Investors should consult a qualified adviser for personal investment decisions.
